Description
CC-671 is a dual TTK/CLK2 inhibitor. It acts by inhibiting the phosphorylation of KNL1 and SRp75, direct substrates of TTK and CLK2. It is a monotherapy candidate for treatment of triple negative breast cancer.
Product Unit Size | Cost | Quantity | Stock |
---|
CC-671 is a dual TTK/CLK2 inhibitor. It acts by inhibiting the phosphorylation of KNL1 and SRp75, direct substrates of TTK and CLK2. It is a monotherapy candidate for treatment of triple negative breast cancer.
Cas No. | 1618658-88-0 |
---|---|
Purity | ≥98% |
Formula | C28H28N6O4 |
Formula Wt. | 512.57 |
IUPAC Name | 4-{[4-(Cyclopentyloxy)-5-(2-methyl-1,3-benzoxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino}-3-methoxy-N-methylbenzamide |
Synonym | CC 671, CC671 |
Store Temp | -20°C |
---|---|
Ship Temp | Ambient |
MSDS | |
---|---|
Info Sheet |
Riggs J., Nagy M., et al. The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen. J Med Chem. 60(21):8989-9002 (2017). PMID: 28991472.
Zhu D., Xu S., et al. Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G1-S Checkpoint. Mol Cancer Ther. 17(8):1727-38 (2018). PMID: 29866747.
Polyether neurotoxin found in Karenia brevis; N...
Selective Cannabinoid receptor 2(CB2) inverse a...
Endogenous precursor to all steroid hormones; T...
Non-steroid; AR antagonist.
Endogenous peptide hormone fragment, involved i...
Endogenous steroid hormone; ERβ, NMDA, σ1 ago...
2’-Benzoylcarbonyl D-seco-Taxol is an impurit...
Fluorogenic substrate used to measure serine pr...
Thiol derivative, antioxidant.
Broad-spectrum antibiotic
α1-adrenergic antagonist.
Camptothecin derivative; topoisomerase I inhibi...
DPP4 inhibitor.
β1-adrenergic antagonist.
Synthesis intermediate
Stilbene, resveratrol analog.
Corticosteroid; glucocorticoid agonist.
Tyrosine kinase inhibitor.
Tryptamine; 5-HT1B/1D agonist, TRPV1 antagonist...